EditorialEditorial
Open Access

Introduction and impact of the young breast cancer in China consensus

Xin Yang, Chao Dong and Qiang Liu
Cancer Biology & Medicine December 2025, 20250523; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0523

References

  1. 1.↵
    2. Cathcart-Rake EJ,
    3. Ruddy KJ,
    4. Bleyer A,
    5. Johnson RH.
    Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncol Pract. 2021; 17: 305–13.
    OpenUrlPubMed
  2. 2.↵
    2. Bray F,
    3. Laversanne M,
    4. Sung H,
    5. Ferlay J,
    6. Siegel RL,
    7. Soerjomataram I, et al.
    Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Chinese Society of Clinical Oncology, Experts Committee on Breast Cancer, China Anti-Cancer Association, the Society of Breast Cancer, Chinese Medical Association, Chinese Society of Breast Surgery. Expert consensus on the diagnosis and treatment of young breast cancer in China (2022 Edition). Zhonghua Yi Xue Za Zhi. 2023; 103: 387–403.
    OpenUrlPubMed
  4. 4.↵
    2. Yang Y,
    3. Liu J,
    4. Peng M,
    5. Su F,
    6. Xie X,
    7. Liu Z, et al.
    Introduction of a multicenter online database for non-metastatic breast cancer in China. Sci China Life Sci. 2020; 63: 1417–20.
    OpenUrlPubMed
  5. 5.↵
    2. Guo R,
    3. Si J,
    4. Xue J,
    5. Su Y,
    6. Mo M,
    7. Yang B, et al.
    Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999-2017. Chin J Cancer Res. 2019; 31: 653–62.
    OpenUrlPubMed
  6. 6.↵
    2. Yang Y,
    3. Wei W,
    4. Jin L,
    5. He H,
    6. Wei M,
    7. Shen S, et al.
    Comparison of the characteristics and prognosis between very young women and older women with breast cancer: a multi-institutional report from China. Front Oncol. 2022; 12: 783487.
  7. 7.↵
    2. Wang X,
    3. Xia C,
    4. Wang Y,
    5. Qi Y,
    6. Qi X,
    7. Zhao J, et al.
    Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study). EClinicalMedicine. 2023; 64: 102243.
  8. 8.↵
    2. Yap YS,
    3. Lu YS,
    4. Tamura K,
    5. Lee JE,
    6. Ko EY,
    7. Park YH, et al.
    Insights into breast cancer in the east vs the west: a review. JAMA Oncol. 2019; 5: 1489–96.
    OpenUrlPubMed
  9. 9.↵
    2. Li WQ,
    3. Li R,
    4. Liu PF,
    5. Huang YB.
    Discussion of breast cancer screening model in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2016; 37: 1039–43.
    OpenUrlPubMed
  10. 10.↵
    2. Wu Z,
    3. Liu Y,
    4. Li X,
    5. Song B,
    6. Ni C,
    7. Lin F.
    Factors associated with breast cancer screening participation among women in mainland China: a systematic review. BMJ Open. 2019; 9: e028705.
  11. 11.↵
    2. Wan Q,
    3. Su L,
    4. Ouyang T,
    5. Li J,
    6. Wang T,
    7. Fan Z, et al.
    Comparison of survival after breast-conserving therapy vs mastectomy among patients with or without the BRCA1/2 variant in a large series of unselected Chinese patients with breast cancer. JAMA Netw Open. 2021; 4: e216259.
  12. 12.
    2. van den Broek AJ,
    3. Schmidt MK,
    4. van ’t Veer LJ,
    5. Oldenburg HSA,
    6. Rutgers EJ,
    7. Russell NS, et al.
    Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg. 2019; 270: 364–72.
    OpenUrlPubMed
  13. 13.↵
    2. Su L,
    3. Xu Y,
    4. Ouyang T,
    5. Li J,
    6. Wang T,
    7. Fan Z, et al.
    Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. Int J Cancer. 2020; 146: 3335–42.
    OpenUrlPubMed
  14. 14.↵
    2. Kuchenbaecker KB,
    3. Hopper JL,
    4. Barnes DR,
    5. Phillips KA,
    6. Mooij TM,
    7. Roos-Blom MJ, et al.
    Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Am Med Assoc. 2017; 317: 2402–16.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Antoniou A,
    3. Pharoah PD,
    4. Narod S,
    5. Risch HA,
    6. Eyfjord JE,
    7. Hopper JL, et al.
    Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117–30.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Burns E,
    3. Koca E,
    4. Xu J,
    5. McLean E,
    6. Lee R,
    7. Patel T, et al.
    Measuring ovarian escape in premenopausal estrogen receptor-positive breast cancer patients on ovarian suppression therapy. Oncologist. 2021; 26: e936–e42.
    OpenUrlPubMed
  17. 17.↵
    2. Bellet M,
    3. Gray KP,
    4. Francis PA,
    5. Láng I,
    6. Ciruelos E,
    7. Lluch A, et al.
    Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST substudy. J Clin Oncol. 2016; 34: 1584–93.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Fisher B,
    3. Costantino JP,
    4. Redmond CK,
    5. Fisher ER,
    6. Wickerham DL,
    7. Cronin WM.
    Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86: 527–37.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Liu J,
    3. Jiang W,
    4. Mao K,
    5. An Y,
    6. Su F,
    7. Kim BY, et al.
    Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015; 150: 439–45.
    OpenUrlPubMed
  20. 20.↵
    2. Paluch-Shimon S,
    3. Cardoso F,
    4. Partridge AH,
    5. Abulkhair O,
    6. Azim HA,
    7. Bianchi-Micheli G, et al.
    ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022; 33: 1097–118.
    OpenUrlPubMed
  21. 21.
    2. Sessa C,
    3. Balmaña J,
    4. Bober SL,
    5. Cardoso MJ,
    6. Colombo N,
    7. Curigliano G, et al.
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023; 34: 33–47.
    OpenUrlCrossRefPubMed
  22. 22.
    NCCN Clinical Practice Guidelines in Oncology: breast cancer. Version 6.2024. National Comprehensive Cancer Network. Available from: https://www.nccn.org/.
  23. 23.
    NCCN Guideline. Genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate. Version 2.2025. National Comprehensive Cancer Network; 2025. Available from: https://www.nccn.org/.
  24. 24.
    2. Bedrosian I,
    3. Somerfield MR,
    4. Achatz MI,
    5. Boughey JC,
    6. Curigliano G,
    7. Friedman S, et al.
    Germline testing in patients with breast cancer: ASCO – Society of Surgical Oncology Guideline. J Clin Oncol. 2024; 42: 584–604.
    OpenUrlPubMed
  25. 25.
    2. Oktay K,
    3. Harvey BE,
    4. Partridge AH,
    5. Quinn GP,
    6. Reinecke J,
    7. Taylor HS, et al.
    Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018; 36: 1994–2001.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Lin J,
    3. Ouyang Y,
    4. Li Y,
    5. Jin L,
    6. Li S,
    7. Liu Y, et al.
    Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor-positive breast cancer. J Natl Cancer Inst. 2024; 116: 1587–97.
    OpenUrlPubMed
  27. 27.↵
    2. Lin J,
    3. Zheng S,
    4. Liu Q.
    Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists. Cancer Treat Rev. 2025; 133: 102879.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section